Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Viridian Therapeutics Inc(VRDN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for VRDN
10/28/2026: VRDN (3-star) is a STRONG-BUY. BUY for 1 day. Simulated Profits (0.00%). Updated daily EoD!
Viridian Therapeutics is a clinical-stage biotechnology company focused on developing specialized antibody therapies for thyroid eye disease and other autoimmune conditions. Its primary strength lies in a targeted pipeline that seeks to offer improved patient convenience through innovative dosing. The main growth opportunity hinges on the successful progression and regulatory approval of its lead candidates, which could compete in a significant orphan disease market. Key risks include intense competition from established biopharma, high dependency on clinical trial outcomes, and the lack of current commercial revenue. The stock may suit growth-oriented investors with a high risk tolerance who are monitoring upcoming pivotal clinical data readouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Viridian offers high-growth potential driven by its late-stage pipeline in the rare disease space. |
| Momentum investor | Mixed fit | Performance is highly sensitive to clinical trial announcements and regulatory news, requiring a positive momentum signal. |
| Value investor | Weak fit | The company is not currently profitable and does not possess traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends, prioritizing capital for clinical development. |
| Low-risk investor | Weak fit | As a clinical-stage biotechnology company, it carries inherent high clinical and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience large price swings around trial results and regulatory decisions. |
| Valuation risk | Medium / high | Valuations are highly speculative, based on future commercial success rather than current earnings. |
| Competition risk (Biologics/TED) | High | The market includes established competitors with significant commercial infrastructure. |
| Business quality | Medium | While the platform is scientifically sound, the business is not yet established via recurring commercial revenue. |
| Dividend income | Low / none | The company reinvests all capital into growth and does not distribute cash to shareholders. |
| Execution risk | High | Success depends entirely on the ability to conduct complex clinical trials and navigate FDA approval processes. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 112.18% | Avg. Invested days 40 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.73B USD | Price to earnings Ratio - | 1Y Target Price 36.2 |
Price to earnings Ratio - | 1Y Target Price 36.2 | ||
Volume (30-day avg) 2.1M shares | Beta 1.1 | 52 Weeks Range 13.18 - 34.29 | Updated Date 10/28/2026 |
52 Weeks Range 13.18 - 34.29 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.39 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical Development | Clinical trial development and future commercialization of monoclonal antibody therapeutics. | The company earns money by developing drugs; its future value depends on successfully getting these drugs approved and sold to patients. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1.01 | Enterprise Value 2.00B | Price to Sales(TTM) 38.37 |
Enterprise Value 2.00B | Price to Sales(TTM) 38.37 | ||
Enterprise Value to Revenue 28.17 | Enterprise Value to EBITDA -3.18 | Shares Outstanding 113.29M | Shares Floating 100.79M |
Shares Outstanding 113.29M | Shares Floating 100.79M | ||
Percent Insiders 0.17 | Percent Institutions 126.75 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.